That is very important, because the way a protein in the human body folds identifies if a pharmaceutical will be able to bind to that protein and work. Simply put, we have to know how these proteins fold if we want a drug to work. Historically, this has actually been an experimental process (angel investor). And now, Alpha, Fold can predict protein folding with 92. 4% accuracy. That's going to make it much simpler to create drugs that do what they're designed to do. This was a development nearly no one saw. However it's going to have extensive ramifications for curing illness. I anticipate that Alpha, Fold will be 98% precise by the end of 2021.
And, of course, there will be a lot of financial investment chances in this area, too. Shifting subjects It's going to be a great year for bitcoin. I'm bullish on it in 2021 (jeff brown top stock pick 2021). That said, I still believe bitcoin will continue to be unstable. We're close to all-time highs. I would not be shocked if it pulled back perhaps considerably before going higher - genetic sequencing companies jeff brown. I have actually been covering bitcoin for a long period of time now. One of the very first research study reports I ever published was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that initial suggestion, I titled my report "What's the Big Deal With Bitcoin?" That shows you where the discussion was at the time. We were mostly educating readers. However that's not the huge concern any longer. Now we're seeing institutional money lastly take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, specific niche enterprise. Mass, Mutual is a relied on 170-year-old organization. So think of that. In 5 years, we went from informing readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
And that's a huge factor I'm bullish on it this year. second wave. Regards, Jeff Brown, Editor, The Bleeding Edge I have a reward prediction 2020 was a record year for IPOs. 552 U.S. companies went public the most in more than 20 years. These business raised an overall of $172 billion. That's an all-time high beating the previous yearly record by 43%. I anticipate 2021 will be another record year in IPOs. There are so numerous fantastic personal companies on the verge of hitting the general public markets And I have actually been dealing with a new way for you to invest even before these business go public.
This chance has been developing over the last couple of years. I can't wait to inform you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to learn all the details. Go right here to book your area for complimentary.
Emma Walsh here, handling editor of the Journal. Routine Journal readers understand that tech isn't our usual beat (jeff brown biotech stock pick for 2020). And when it concerns tech investing, we leave it to the professionals. Thankfully, we have a number of such professionals in our Rolodex. Our coworker Jeff Brown will be familiar to our longtime readers. He is one of the most accomplished tech investing specialists we understand (brownstone research). In fact, he had several triple-digit returns in his Brownstone Research study portfolios in 2015. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to have a look at the huge image and forecast what's simply around the corner.
That consists of things like 5G networks, biotech, artificial intelligence, and far more. These patterns are experiencing exponential development and producing amazing opportunities for investors. I want to make certain all our readers are gotten ready for what's next. And with that in mind, let me draw the picture of what I see can be found in the next 12 months Our new 5G (fifth-generation) cordless networks are a subject I have actually been covering for years now. what is the legacy report predicting. But in spite of what numerous readers may believe, this is a pattern that's just getting begun. Although the COVID-19 pandemic disrupted supply chains in 2015, an excellent 250 million 5G-enabled devices were still offered.
And all of this eventually resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by 2 months (diplomatic relations). Losing two months of production and sales truly affects how many 5G gadgets are sold in the calendar year. When you think about all of that, offering 250 million systems is exceptional. More significantly, the delays brought on by the pandemic produced a lots of bottled-up need. And that demand is now going to be pushed into 2021. In reality, I anticipate that more than 500 million 5G devices will be delivered in 2021 - jeff brown biotech stock. And that's not my only 5G forecast When I have actually discussed 5G in the past, I've explained its three various phases.
In Phase 2, 5G gadgets go on sale. 5G phones and other items start to reach customers. And in Stage 3, 5G services start to be used (exponential growth). That's when we start to see applications operating on 5G networks. Think of things like enormous multiplayer games over a smart phone. That's not possible with 4G. It will be with 5G. And my second 5G forecast for 2021 is that we will start Phase 3 by this summertime. This starts something of a virtuous cycle: Many people don't actually care about the technology. However they will care if there are amazing applications that can only be accessed with a 5G phone.
That causes more 5G apps being established. In fact, 5G is going to open up a suite of extraordinary applications: self-driving cars, the Internet of Things, robotic surgery, and more. All of these innovations require 5G. The financial investment chances moving forward will be enormous. Stepping far from 5G, the next important technology I predict in 2021 is CRISPR genetic editing. CRISPR means "clustered routinely interspaced brief palindromic repeat." It's a mouthful. But it is among the most exciting advancements in biotechnology. At a high level, CRISPR is an innovation that can edit our genetic makeup as if it were software.
The program can crash or not operate properly. CRISPR uses a comparable idea however with our hereditary code. "Typos" in our genome can lead to illness. CRISPR can fix these "typos." For years, CRISPR was primarily a specific niche technology that wasn't well understood. And during that time, there were truly only three business operating in this space. But things are altering. CRISPR is no longer just theoretical. We're seeing actual outcomes. We're dealing with illness and seeing that this technology simply works. And as an outcome, a "2nd crop" of early-stage CRISPR business is going public and delivering extraordinary returns. This whole industry is effectively a greenfield opportunity.
There's room for lots of companies to exist in this area. jeff brown biotech picks. And there will be more. That's my forecast for CRISPR in 2021. I forecast that 2 or three more hereditary editing companies will hold their IPOs. Sticking to biotechnology, we are seeing fantastic things occurring at the merging of biotech and synthetic intelligence (AI). Google's AI subsidiary, Deep, Mind, simply revealed at the end of 2020 that its latest Alpha, Fold software can accurately anticipate the folding of a protein based exclusively on its amino acid series with 92. 4% accuracy. That is essential because the way a protein in the human body folds determines if a pharmaceutical will be able to bind to that protein and work.
Historically, this has actually been an experimental procedure. But now, Alpha, Fold can forecast protein folding with 92. 4% precision. That's going to make it a lot easier to develop drugs that do what they're developed to do. And here's my next prediction. I anticipate that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not just one however numerous drug therapies produced using this innovation. This was among those advancements that nearly nobody observed. However it's going to have extensive ramifications for curing illness. And, naturally, there will be plenty of financial investment opportunities in this area, too.
It's going to be a good year for bitcoin. I'm bullish on it in 2021. That stated, I still think bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be surprised if it pulled back perhaps substantially prior to going greater. I've been covering bitcoin for a long period of time now. One of the first research reports I ever released was on bitcoin - social media. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for anybody who followed my recommendation. However at the time of that initial suggestion, I entitled my report, "What's the Big Offer With Bitcoin?" That shows you where the conversation was at the time.
But no one is asking that concern anymore. Now, we're seeing institutional money lastly taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, niche business. exponential tech investor. Mass, Mutual is a 150-year-old institution. So consider that. In 5 years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge reason that I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another bonus forecast In 2021, we're going to have another record year in IPOs. One site reports that Jeff Brown deserves about $27. 5 million and declares the details depends on date as of February 2021, however we might not independently validate this claim. Offered Jeff Brown's past, he likely has a considerable net worth, however we can't hammer down an accurate figure at this minute. Brown is best known for his sage-like ability to select winning technology stocks. He invested more than 25 years researching innovation business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's extensive experience provides him an outstanding viewpoint on the market. He's always on the hunt for new chances, and he shares much of his finest picks in the Future Report.
That's full marks, but it's not absurdly reasoned. Brown has an exceptional reputation as a stock-picker, and he successfully anticipated a few of the most significant financial events of the past 20 years. Although he doesn't appear to release his choices to the public, the service's success is a direct sign of Brown's stock-picking expertise. Nobody on Wall Street gets it ideal every time, but Jeff Brown's accurate forecasts have actually earned him legions of devoted fans. That says a lot about his ability. The Future Report is published by Brownstone Research, a prominent financial research study publisher. Brownstone Research provides several research services with a variety of specializations - tech predictions.
The company is also connected with Bonner & Partners, another well-respected research study publisher - jeff brown biotech picks. On its site, Brownstone states its objective is to offer retail investors with professional-grade research study: "For too long, the very best investment research has not been offered to specific financiers. It has actually been normally reserved for investment banks, hedge funds, personal equity, and high-net-worth customers. jeff brown biotech stock. The mission of Brownstone Research study is to make that sort of exclusive research readily available to any investors wanting to acquire an edge in the marketplaces. The goal is easy to deliver special and lucrative financial investment research found no place else." -Brownstone Research website excerpt from the Jeff Brown is the founder of Brownstone Research, and he likewise acts as the company's Chief Financial investment Analyst.
With Brown guiding the ship, Brownstone Research is a powerhouse publisher with lots to offer its customers. After decades of consistent success at the helm of top-tier companies like Tesla and Area, X, Elon Musk is a home name throughout many of America. If you know even a little bit about the market, you know that he has a credibility as a King Midas of sorts. jeff brown genetic sequencing stock. Everything he touches turns to gold! Jeff is well aware of Elon Musk's executive prowess, so he always has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next huge job.
In truth, Brown thinks S.A.V. jeff brown 2021 stock predictions. could be "the biggest pattern of the 2020s, and he's not alone. Take a look at these quotes from other widely known S.A.V. bulls: Elon's next huge act will be marrying 2 cutting-edge technologies: expert system and electrical cars. Musk hopes the mix will assist him establish the first fully-autonomous, self-driving vehicles ever. It's absolutely nothing except the automotive industry's Holy Grail. As you know, electrical vehicles and self-driving car stocks have actually been big this year, however the Wall Street device has actually approved hype without much tangible outcome. Regardless of an extreme boost in competitors over the past couple of years, Brown still thinks Musk has the finest opportunity of putting all of it together.
tech might be the magic string that connects everything together. S.A.V. means Shared Autonomous Vehicle, and it might be the future of transportation. Essentially, this innovation would allow you to lease your car as a self-governing, self-driving taxi when you're not utilizing it. You just leave the cars and truck and press a button on an app that informs the vehicle to "join the fleet." Next thing you know, you're unwinding on your sofa while your vehicle shuttles ride-sharers around town. Best of all, you get to keep a large portion of the earnings. It sounds crazy, however it might be closed than you think.